NeuroEyeCoach Study Highlights Benefits for Vision Rehabilitation in Home and Clinic Settings
A new study on NovaVision's NeuroEyeCoach demonstrates significant improvements in visual search performance for patients, whether used at home or in a clinic, supporting its role in vision rehabilitation.
A recent study published in Springer May 2025 Experimental Brain Research has provided further evidence supporting the efficacy of NovaVision's NeuroEyeCoach in improving visual search performance and reducing visual disability for patients, whether the therapy is accessed at home or in a clinic setting. This study, a collaboration between the Neurorehabilitation unit of the Neuromotor and Cognitive Rehabilitation Research Centre, University of Verona, Italy, and NovaVision, compared the outcomes of 95 patients using the therapy at home with 31 patients attending a clinic in Verona.
The findings concluded that NeuroEyeCoach is an effective tool for the rehabilitation of vision loss in both settings, with no significant differences in the benefits to patients' activities of daily living between the two groups. This supports the growing trend towards digital health solutions that can be accessed remotely, offering a low-cost, widely accessible option for vision rehabilitation.
NeuroEyeCoach, part of Vycor Medical, Inc.'s NovaVision division, was previously validated in a 296-patient peer-reviewed clinical study published in Cortex, which remains the largest published eye movement training study to date. The therapy has shown to improve search times by 87% and reduce errors in 80% of patients, marking a significant advancement in the treatment of visual impairments caused by stroke or brain injury.
For more information on Vycor Medical and its innovative solutions, visit https://www.vycormedical.com, https://www.vycorvbas.com, or https://www.novavision.com.